

Background and Overview of Proposed Investigation into the Risk of Benzene-Induced Haematopoietic Disease

This document describes a project to investigate the dose response and mechanistic aspects of the haematological effects of benzene exposure in a population of workers in Shanghai, China (PRC) . In addition, it is intended to examine the reproducibility of reports from an earlier study of a nationwide occupational cohort in China linking benzene exposure with Non-Hodgkin's lymphoma (NHL). That study also was interpreted to indicate that average benzene exposures as low as 5 ppm could result in acute myelogenous leukemia (AML) and in a range of chromosomal alterations. The project described below will include parallel case control studies of NHL and AML, an investigation of the role of non-neoplastic diseases such as aplastic anemia (AA) and myelodysplastic syndrome (MDS) as a progression to AML, and determination of the dose-response relationship between benzene exposure and selected biomarkers of both exposure and effect.

Background: Importance of Benzene-Based Risk Estimates

An accurate understanding of the true relationship between benzene exposure and the risk of hematopoietic disease such as AML would be of tremendous benefit to the petroleum industry and other industries in which benzene occurs as a constituent of products, precursors or waste streams. Currently, regulatory bodies often rely on conservative default assumptions that overestimate risk whenever there is uncertainty about aspects of the risk estimation process. One example is the assumption that the relationship between benzene exposure and hematopoietic cancer is linear and passes through zero. That is, no exposure to benzene, however small, is without some finite risk of causing some form of leukemia. Another is that all forms of leukemia may result from benzene exposure, rather than just the more restrictive class of acute myeloid types that is most strongly supported by the available literature. Moreover, the application of the Precautionary Principle, whilst consistent with European practice in many areas of workplace and public health protection, should not be seen as rationale to move away from quantitative risk assessment. Soundly based regulatory action still requires robust data sets that instill confidence in risk estimates.

Data Gaps and Uncertainties

There are a number of areas of uncertainty regarding benzene-induced hematopoietic disease that, if answered, have the potential to result in significant reductions in estimates of benzene-related risks. These are:

- 1.) The shape of the dose-response relationship between benzene exposure and selected hematological diseases (including the possibility of a true threshold);
- 2.) Clearly identifying those types of hematopoietic cancer that can be causally related to benzene exposure. Currently, only acute myeloid leukaemias have a strong causal relationship, but some regulatory agencies still assume that all leukaemias can result from benzene exposure, and base risk estimates on this assumption;
- 3.) Clarification of the role of non-cancer hematological diseases in the aetiology of benzene-induced leukemia. If bone marrow toxicity is a prerequisite for subsequent leukaemia, then there must *a priori* be a threshold;
- 4.) Identification of similarities between leukaemia secondary to benzene exposure and the much better understood and studied leukaemias secondary to administration of certain chemotherapeutic drugs used to treat some primary cancers. This category of uncertainty includes the ability to identify a marker or other characteristic of leukaemia induced by exposure to benzene, rather than those resulting from errors in DNA repair or other "natural causes";

- 5.) Clarification of the quantitative relationship between benzene exposure and potential indicators of exposure or of effect. This includes determining which of these two categories potential indicators actually represent. This is important because of the possibility of using “biomarkers” to extend the dose response-curve for cancer to lower exposures by using surrogates for the actual leukaemogenic response.

Project Description

The proposed project consists of three highly integrated aspects:

- 1.) A population-based case control study to investigate the potential relationship between benzene exposure and both NHL and AML including an attempt to define a quantitative potency for the AML response;
- 2.) A hospital/clinic-based investigation of the relationship between non-neoplastic diseases of the bone marrow and AML to determine if there is a progression through stages of bone marrow cytotoxicity to an ultimate leukaemogenic response. This study would also attempt to define, both a potency and the shape of the dose-response for these “precursor” diseases;
- 3.) A “transitional” study to investigate the quantitative relationships between benzene exposure and potential early indicators of both exposure and effect in a focused population of benzene-exposed shoe manufacturing workers.

All three of these aspects are highly integrated in that the potential cases for the case control studies will have their diagnoses confirmed and their subtype and viral status determined by the same laboratory that will conduct the cytogenetic analyses which are part of the third portion of the project. The progression study, the second portion of the project, will use the shared laboratory facilities, and many of the “cases” in the AML case-control study may also be included in the progression study.

Case-Control studies

A collaboration between the US National Cancer Institute and the Chinese Academy of Medicine (the NCI/CAPM study) was published as a cohort study of Chinese workers occupationally exposed to benzene in a number of industries. The NCI/CAPM study reported an association between benzene exposure and Non-Hodgkin’s lymphoma. This association has not been reported in any other study of benzene health effects, and contradicts the general scientific consensus that acute myelogenous leukaemia (AML) is the only haematopoietic cancer which can be clearly associated with human exposure to benzene. The study also has reported an association between benzene exposure and AML, but interpreted the results to indicate that average benzene exposures of around 5 ppm could lead to AML. An association between AML and benzene exposure at these levels has not been reported previously and is inconsistent with previous studies and the pattern of other disease endpoints encountered in the NCI/CAPM study.

This project will initiate a population-based case-control epidemiology study of NHL and AML in the population of Shanghai. The case-control design will allow a focussed examination of the assertion that benzene exposure can cause NHL. NHL is not a single disease but, rather, is a collective of over a dozen phenotypically distinct haematopoietic cancers. As has been done traditionally, the NCI/CAPM study looked only at the lumped cancers. The proposed study design includes subtyping each individual case to determine if a positive response is confined to only one component of NHL. In addition, the viral status of each case will be determined because it is known that active infection with any of a number of viruses has been causally related to increased risk of NHL. Confounding by this factor may explain the NCI/CAPM observation. This portion of the project, as well as the other two listed above, will include independent analysis of benzene exposures. This will also provide an additional input to gauge the validity of the exposure estimation procedures used by the NCI in their publications. If the quality of the exposure data permit, an estimate of the quantitative potency (slope factor) will be made for any cancer type with a positive association with benzene

exposure. Currently, we have contacts with the Departments of Public Health and Hematology of Shanghai Medical University. Through that institution we have contacts with the Shanghai Tumor Registry and the Shanghai Center for Disease Control, which is the governmental repository for workplace exposure information. Protocols are under current development based upon the results of an in-depth feasibility study conducted in August, 1999 by Exxon Biomedical Sciences, Inc. and Dr. Richard Irons of the University of Colorado.

Disease Progression/Molecular Epidemiology Study

Researchers, using subsets of workers from the NCI/CAPM cohort study, have published papers that report an association between benzene exposure and a number of chromosomal abnormalities. Some of these abnormalities are reportedly associated with airborne benzene concentrations as low as 5 ppm. The significance of these studies is difficult to interpret due to problems with exposure assessment in the NCI/CAPM cohort study and with the way in which the exposures are stratified. In addition, dermal exposure to benzene appears to have been largely ignored. One other study has reported significant genetic predispositions to benzene-induced hematotoxicity. Although qualitatively plausible, evaluation of the magnitude of the effects is again difficult because of the exposure and stratification issues previously mentioned.

This project will utilize individuals identified as part of the case-control epidemiology study to investigate genetic effects and disruption of regulatory processes on the hematopoietic system. This study will also allow an independent evaluation of the exposure-response nature of these effects in a population more highly exposed than occurs in the U.S. or Europe. This study will identify those individuals with hematopoietic disease, MDS or AML, that can be reliably attributed to benzene exposure, in order to identify unique characteristics of benzene-induced disease. This may allow a definitive identification of hematopoietic effects unique to benzene exposure, and establish a link between benzene-induced leukemias and other leukemias secondary to chemical exposure (mainly alkylation chemotherapy) about which much is already known. The study will be performed by Dr. Richard Irons of the University of Colorado with the collaboration and assistance of investigators from the Departments of Hematology and Public Health of Shanghai Medical University.

The above investigators will also be involved in an examination of the relationship between AML and other non-neoplastic haematopoietic diseases. The combination of a relatively stable population (geographically) with both hospital and occupational records of bone marrow related disease has created the possibility of investigating this relationship. Workers in benzene-related areas are monitored for excessive exposure (reported to the Center for Disease Control and Prevention (CDC) as "benzene poisoning") by means of annual blood counts. It has been hypothesized that AML must be preceded by some degree of toxicity to the haematopoietic system. Validation of this hypothesis would provide critical support for a nonlinear (sublinear) dose response of hematopoietic effects due to benzene exposure, and would imply a non-zero threshold exposure to benzene below which there would be no apparent risk of AML, etc. It is not clear at this time how reliably individuals with benzene poisoning can be located, but cases of MDS or aplastic anemia (AA) treated in hospitals may be more easily located. These issues will have to be resolved during the course of the investigations.

Transitional Study of the Shoe Manufacturing Industry

One area of benzene research that has received a lot of attention in the last few years is the attempt to identify early biological indicators that predict a later event such as AML or serious forms of bone marrow toxicity such as MDS or AA. These early indicators have also been referred to as "biomarkers". Some endpoints which have been measured, such as protein adducts of benzene metabolites, are clearly indicators only of exposure to benzene (although there may be some complicated relationship with biological responses). Some endpoints,

such as certain cytogenetic abnormalities, have been claimed to be indicators of future effect. The NCI/CAPM researchers have published several papers investigating both phenomena. However, two problems remain. The first is distinguishing between the two types of indicators. At this time no biological predictor of benzene-induced leukaemia has been unequivocally identified. The second problem, as with other portions of the NCI/CAPM studies, is that the benzene exposure information either relies on uncertain estimates of past exposure, or has presented current exposure monitoring data in a way that ascribes effects from a wide range of exposures to a single mean value from that range. No publication exists in the scientific literature that has attempted to establish an exposure response relationship for genetic effects that is based upon several sets of data points.

The objective of this series of studies is to investigate the relationship between benzene and various blood dyscrasias and cytogenetic abnormalities in the Shanghai shoe manufacturing industry. The dose-response will be investigated in relation to various types of benzene exposure metrics. This study will take advantage of the wide range of benzene exposures in this occupation, which will maximize the possibility of seeing non-linearity of any dose response that exists. Specific aims of this facet of the overall project are:

- 1.) To define benzene dose response patterns for alterations in blood cell counts, bone marrow cytotoxicity and chromosomal alterations;
- 2.) To define the most relevant exposure indicators for each of the effects in “1”;
- 3.) To assess if the dose response patterns are affected by the presence of other environmental compounds such as toluene or xylene which commonly are co-exposures with benzene;
- 4.) To assess if the dose response patterns are altered by the presence of reported susceptibility factors in exposed individuals;
- 5.) To define the relationship between external benzene exposure and selected internal measures of exposure.

The extent of specific aim 5 may be affected by ongoing research by the Health Effects Institute that is investigating several of these relationships.

Location

The location for the proposed project is Shanghai, China. Shanghai is a major population center with approximately 14 million individuals living in the local area. Shanghai supplied a large proportion of the individuals studied in the NCI/CAPM epidemiological study, and virtually all of the subjects for the ancillary studies of chromosomal alterations. Shanghai presents the unique situation of a large number of workers with documented exposures to benzene at levels that have not existed in North America or Western Europe since the 1940's or 50's. A feasibility study group funded by the API Benzene Task Force was shown records of industrial hygiene monitoring of work areas where benzene was routinely used and where airborne benzene concentrations occasionally were in excess of 100 ppm, and where a rare data point could exceed 200 ppm. Although many air samples indicated exposures of less than 10 ppm, concentrations in the range of 10 – 50 ppm were common. The regional agency in charge of maintaining occupational health records, the Center for Disease Control and Prevention, has a computerized database of industrial hygiene (IH) monitoring data extending back to the mid 1980's. In addition to air monitoring data, blood counts of exposed workers are routinely made on an annual basis. These data are also maintained in computerized form by the local CDC offices. Shanghai also contains a major medical school, Shanghai Medical University (SMU), with a School of Public Health and Hematology Department associated with a teaching hospital. This hospital is one of the major hospitals in Shanghai and will serve as a source for identifying potential cases for the proposed studies.

The Investigators

The principal co-investigators who are expected to lead the project are:

Epidemiology

Otto Wong, D.Sc. – Applied Health Sciences, San Mateo, CA

Robert Schnatter, Ph.D. – Exxon/Mobil Biomedical Sciences, Annandale, NJ

Hua Fu – Deputy Dean, Shanghai Medical University School of Public Health, Shanghai, PRC

Hematology/Molecular Biology

Richard Irons, Ph.D. – University of Colorado Health Sciences Center, Denver, CO

Guowei Lin, M.D. – Director, Center of Clinical Epidemiology, Hua Shan Hospital, Shanghai, PRC

Industrial Hygiene

Wei Lu – Deputy Director General, Shanghai Municipal Center for Disease Control and Prevention
Shanghai, PRC

Thomas Armstrong, C.I.H. – Exxon/Mobil Biomedical Sciences, Inc., Annandale, NJ

The above list does not limit the possibility that additional investigators may be involved in the future, but these identified individuals have been involved in the development of project protocols.

Scientific Review Committee

In order to ensure the objectivity of this project, a committee of independent experts in disciplines critical to the conduct of this project will be recruited to provide oversight. These disciplines would include epidemiology, hematology, oncology, toxicology, industrial hygiene, genetics and bioethics. The responsibilities of this group would include approval of any changes to the study protocols, changes in the scope of the research and manuscripts submitted for publication that report the results of the research. It is anticipated that this group would meet at least annually to review the research progress, as well as by teleconference or other means, as necessary, to discharge its duties.

Project Duration

The project as described is expected to last a period of 5 years.